aster.cloud aster.cloud
  • /
  • Platforms
    • Public Cloud
    • On-Premise
    • Hybrid Cloud
    • Data
  • Architecture
    • Design
    • Solutions
    • Enterprise
  • Engineering
    • Automation
    • Software Engineering
    • Project Management
    • DevOps
  • Programming
  • Tools
  • About
aster.cloud aster.cloud
  • /
  • Platforms
    • Public Cloud
    • On-Premise
    • Hybrid Cloud
    • Data
  • Architecture
    • Design
    • Solutions
    • Enterprise
  • Engineering
    • Automation
    • Software Engineering
    • Project Management
    • DevOps
  • Programming
  • Tools
  • About
  • Tech

Adaptive Biotechnologies And Microsoft Launch Virtual ImmuneRACE Study To Inform Novel COVID-19 Diagnostics To Address Unmet Needs In Testing

  • relay
  • May 8, 2020
  • 4 minute read

Adaptive Biotechnologies Corp. announced it has begun enrolling a virtual clinical study, ImmuneRACE, as part of a broader effort it has undertaken with Microsoft Corp. to rapidly map and measure the immune response to the COVID-19 virus to inform improved diagnostics to fulfill the need for more reliable testing. The study calls for 1,000 participants in select U.S. metropolitan areas impacted by COVID-19. De-identified data will be made freely available to public health officials, academia and industry to help accelerate solutions to the pandemic. LabCorp (NYSE: LH), through its Covance drug development business, will manage the collection of blood samples and nose/throat swabs from participants in the comfort and safety of their own homes.

There are currently two types of tests for COVID-19. PCR tests indicate the presence of live virus from a nose or throat swab, and serology tests indicate exposure to and potential immunity against the virus by measuring the presence of antibodies in the blood. Adaptive and Microsoft believe a third type of test can potentially help address current challenges with testing, resulting in the following scenarios:

  • Complementary or alternative diagnostic testing for individuals with known exposures or symptoms
  • Ability to triage patients and inform treatment strategies based on risk
  • Ongoing immunity surveillance testing of the population to inform decisions on restrictions

“We’ve spent the past decade learning how the adaptive immune system naturally detects and treats all disease, and we are well-positioned to apply our immune medicine platform specifically to COVID-19. We’re hopeful that we can contribute important information that will become part of an immune scan to help reopen society,” said Chad Robins, CEO and co-founder of Adaptive Biotechnologies. “As many are sheltering in place wondering how they can help, we wanted to launch ImmuneRACE with Microsoft and give people an opportunity to participate. These efforts are complementary to many global initiatives underway to study the virus itself.”

Read More  How Fleet Management Gets Easier With Smart Analytics On Google Cloud

As part of the study, the partners will measure the presence of specialized cells of the immune system in the blood, called T cells, that identify the disease early on and proliferate to combat the infection. Together, Adaptive and Microsoft are mapping and measuring the immune response of T cells specific to many diseases and are now applying their combined capabilities to COVID-19.

“We are dedicated to being part of the solution against COVID-19,” said Peter Lee, corporate vice president, AI and Research, Microsoft. “Immune response data may augment what we have been learning to date to help determine who is at greater risk of developing more severe symptoms and may help with future containment efforts. Anyone who has been affected by COVID-19 holds key information that can help contain and manage the virus.”

In March, the companies announced an expansion of their existing partnership to use machine learning to map the immune system response to many different diseases, including infectious diseases, autoimmune disorders and cancer, at scale to study COVID-19. The information obtained from study participants, including how the immune system identifies the virus and how people are responding to the virus, will be integrated with data obtained from samples provided by hospitals and other institutions across the globe. The accuracy of the immune response signature will be continually improved and updated online in real time as more study samples are sequenced and by using Microsoft’s hyperscale machine learning capabilities and the Azure cloud platform.

Other industry leaders, including Illumina and Providence, have also joined forces with Microsoft and Adaptive to accelerate this critical effort against COVID-19.

Read More  International Day for Universal Access to Information

How to join ImmuneRACE

ImmuneRACE will enroll 1,000 individuals from more than 20 metropolitan areas in the U.S. You can be part of the solution if you are between the ages of 18 and 89 and:

  • Currently have COVID-19
  • Have recently recovered from COVID-19
  • Were exposed to someone diagnosed with COVID-19

If you decide to participate and qualify for the study, you will be asked to provide relevant information about your medical history, symptoms and previous diagnostic tests.

Patients who qualify for the study can schedule a blood draw and swab collection in the convenience of their own home. The phlebotomist completing sample collection will be using appropriate personal protective equipment to safely conduct the visit when entering participant’s homes.

Every effort will be made to ensure confidentiality of protected health information in accordance with HIPAA. Those wanting to participate or learn about more ways to join in the fight against COVID-19 should visit www.ImmuneRACE.com.

About the Adaptive and Microsoft partnership

Adaptive and Microsoft partnered in 2018 to create a TCR-Antigen Map, an approach to translating the genetics of the adaptive immune system to understand at scale how it works. Together we are using immunosequencing and machine learning to map T-cell receptor (TCR) sequences to diseases and disease-associated antigens. Using these data, we aim to develop a blood test for the early and accurate detection of many diseases, translating the natural diagnostic capability of the immune system into the clinic. In 2019, we confirmed clinical signals in two diseases, and established our first proof of concept in Lyme Disease. Adaptive expects to submit our first clinical application to the FDA in 2020.

Read More  Your Computer Can Help Scientists Seeking Potential COVID-19 Treatments
relay

Related Topics
  • Adaptive Biotechnologies
  • Biotechnology
  • Coronavirus
  • COVID-19
  • Illumina
  • ImmuneRACE
  • LabCorp
  • Microsoft
  • Providence
You May Also Like
View Post
  • Software
  • Tech
  • Technology

A New Smartphone Operating System That Puts Privacy First

  • March 10, 2023
View Post
  • Tech

Using IPv6 Unique Local Addresses For Private Connectivity In Google Cloud

  • January 24, 2023
View Post
  • Tech

Get Migrating In 2023: Join Our Upcoming Fireside Chat Featuring Forrester

  • January 24, 2023
View Post
  • Tech

Built With BigQuery: How To Accelerate Data-Centric AI Development With Google Cloud And Snorkel AI

  • January 24, 2023
View Post
  • Insights
  • Tech

What To Expect From CES 2023

  • January 4, 2023
View Post
  • DevOps
  • People
  • Practices
  • Tech

A Better Way To Pass Technical Interviews

  • January 3, 2023
View Post
  • Design
  • Solutions
  • Tech
  • Technology
  • Tools

Solving Internal Search Problems With Dialogflow

  • December 21, 2022
View Post
  • Tech

Best Practices For Managing Vertex Pipelines Code

  • December 10, 2022

Stay Connected!
LATEST
  • 1
    Kubernetes K8s.gcr.io Redirect: What You Need To Know As An Anthos Or GKE User
    • March 30, 2023
  • 2
    Oracle Helidon Taps Virtual Threads For ‘Pure Performance’
    • March 29, 2023
  • 3
    2022 State Of DevOps Report Data Deep Dive: Good Team Culture
    • March 29, 2023
  • 4
    Google Data Cloud & AI Summit : In Less Than 12 Hours From Now
    • March 29, 2023
  • 5
    A 5-Minute Tour Of The Fediverse
    • March 28, 2023
  • 6
    Bringing Observability To Cloud Security
    • March 28, 2023
  • 7
    How AI Can Improve Digital Security
    • March 27, 2023
  • 8
    Docker’s Bad Week
    • March 27, 2023
  • 9
    My First Pull Request At Age 14
    • March 24, 2023
  • 10
    AWS Chatbot Now Integrated Into Microsoft Teams
    • March 24, 2023
about
Hello World!

We are aster.cloud. We’re created by programmers for programmers.

Our site aims to provide guides, programming tips, reviews, and interesting materials for tech people and those who want to learn in general.

We would like to hear from you.

If you have any feedback, enquiries, or sponsorship request, kindly reach out to us at:

[email protected]
Most Popular
  • 1
    Introducing GPT-4 In Azure OpenAI Service
    • March 21, 2023
  • 2
    IBM And Fundación Ikerbasque Partner To Launch Groundbreaking Quantum Computational Center
    • March 24, 2023
  • 3
    Cleveland Clinic And IBM Unveil First Quantum Computer Dedicated To Healthcare Research
    • March 20, 2023
  • 4
    Verify POST Endpoint Availability With Uptime Checks
    • March 24, 2023
  • 5
    Oracle Cloud Infrastructure to Increase the Reliability, Efficiency, and Simplicity of Large-Scale Kubernetes Environments at Reduced Costs
    • March 20, 2023
  • /
  • Platforms
  • Architecture
  • Engineering
  • Programming
  • Tools
  • About

Input your search keywords and press Enter.